TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10442509

Group type: EXPERIMENTAL
Intervention: PGE1 (60 microg given daily i.v. over 2 hours in 250 ml saline, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (250 ml saline, n = 12)
Number of subjects: 24
Study: 7540625

Group type: EXPERIMENTAL
Intervention: Simplified PCR for detection of H. ducreyi
Number of subjects: 133

Group type: COMPARATOR
Intervention: Negative control samples
Number of subjects: 133
Study: 2349372

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg orally, 14 h before)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 393381

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus mitomycin C
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5‐FU plus methyl‐CCNU
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Adriamycin (previously treated patients)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5‐FU plus mitomycin C (previously treated patients)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5‐FU plus methyl‐CCNU (previously treated patients)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: All previously untreated patients
Number of subjects: 139
Study: 28762896

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg/day)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 850
Study: 30815125

Group type: EXPERIMENTAL
Intervention: Prototype knowledge-based application
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clinical pharmacists
Number of subjects: 6
Study: 26923613

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day immediately (Group A)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day 7 days after enrollment (Group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No fluoxetine (Group C)
Number of subjects: 3
Study: 25224993

Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with self-reported depression
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with smoking
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in physically inactive patients
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients during spring season
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with HbA1c >70 mmol/mol (>8.6%)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Reference group of non-depressed patients with a healthy lifestyle (physically active and non-smoking)
Number of subjects: 196
Study: 22179140

Group type: EXPERIMENTAL
Intervention: DXA scans after repositioning
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DXA scans after daily activities
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DXA scans before and after breakfast consumption
Number of subjects: 31
Study: 20004725

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (target blood alcohol level of 50 mg%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17285425

Group type: COMPARATOR
Intervention: Fentanyl (10 microg/kg at induction and 5 microg/kg/h infusion for maintenance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil (3 microg/kg at induction and 1 microg/kg/min infusion for maintenance)
Number of subjects: 50
Study: 16540790

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg orally, once daily for 14 days) with ORS
Number of subjects: 2002

Group type: COMPARATOR
Intervention: ORS alone (control group)
Number of subjects: 2002
Study: 12889593

Group type: EXPERIMENTAL
Intervention: NICHD Maternal Fetal Medicine Units Network trials (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes made to organization and methodology of the Network
Number of subjects: 0
Study: 11196120

Group type: EXPERIMENTAL
Intervention: Proparacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 72
Study: 7855966

Group type: EXPERIMENTAL
Intervention: Sublingual liquid preparation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5 mg tablet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Controlled absorption 3 and 4 mg tablets
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Home trial use of controlled absorption tablets
Number of subjects: 22
Study: 1945288

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7060486

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin administration via jet injector
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subcutaneous heparin administration via disposable syringe
Number of subjects: 10
Study: 31762400

Group type: EXPERIMENTAL
Intervention: 3-month behavioral intervention
Number of subjects: 244

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 244
Study: 30506427

Group type: EXPERIMENTAL
Intervention: Football (1 hour, twice weekly)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (15-30 min telephone session)
Number of subjects: 214
Study: 28700680

Group type: EXPERIMENTAL
Intervention: LF‐MA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HF‐MA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LF‐EA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HF‐EA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Manual acupuncture groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High frequency treatment groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low frequency treatment groups
Number of subjects: 74
Study: 25582611

Group type: EXPERIMENTAL
Intervention: lidocaine 1.5 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: lidocaine 0.5 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo (NaCl 0.9%)
Number of subjects: 54
Study: 24166335

Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 109
Study: 21890776

Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 400 mg once daily (after 14 days of 200 mg)
Number of subjects: 116
Study: 19920270

Group type: EXPERIMENTAL
Intervention: Eszopiclone, 3 mg for the first 14 nights of CPAP
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17353335

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Optimal pain medication (OPM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV) after 2 weeks of OPM
Number of subjects: 34
Study: 14694167

Group type: EXPERIMENTAL
Intervention: Epoetin alpha to maintain hemoglobin between 120 and 130 g/L (group A)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Epoetin alpha to maintain hemoglobin between 90 and 100 g/L (group B)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 155
Study: 10925934

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 5 microg x mL(‐1) (group E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2% lidocaine (group L)
Number of subjects: 12
Study: 8873934

Group type: EXPERIMENTAL
Intervention: Sidestream smoke inhalation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study: 1859006

Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (25% nitrous oxide)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (50% nitrous oxide)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (75% nitrous oxide)
Number of subjects: 47

Group type: COMPARATOR
Intervention: isoflurane and oxygen anesthesia
Number of subjects: 47
Study: 6341271

Group type: EXPERIMENTAL
Intervention: Smoking prevention programme
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Older girls (11-12 years) in treatment group
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Younger boys (10-11 years) in treatment group
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Attitudes and knowledge changes
Number of subjects: 6000
Study: 31003644

Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study: 29653812

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2800 IU daily for 8 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 25661470

Group type: EXPERIMENTAL
Intervention: Nurse-led heart failure specific education session with three-month telephone follow-up in addition to standard medical treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard medical treatment only
Number of subjects: 110
Study: 23032238

Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium sodium phosphosilicate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Toothpaste containing potassium nitrate (positive control)
Number of subjects: 20
Study: 20424826

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 40

Group type: COMPARATOR
Intervention: TOT
Number of subjects: 40
Study: 18281099

Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham Depletion
Number of subjects: 54
Study: 16001659

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha), ribavirin, and ursodeoxycholic acid (UDCA)
Number of subjects: 20
Study: 12423432

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 215

Group type: COMPARATOR
Intervention: Antibiotics/topical treatments
Number of subjects: 215
Study: 10472699

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms kg-1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine and Placebo
Number of subjects: 28
Study: 8910174

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg/kg IV
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg IV
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo IV saline
Number of subjects: 132
Study: 1656521

Group type: EXPERIMENTAL
Intervention: Muesli
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard breakfast with 100 mg miglitol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Muesli with 100 mg miglitol
Number of subjects: 24
Study: 6358896

Group type: EXPERIMENTAL
Intervention: Intravenous timolol treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 31048509

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (8 weeks of aerobic and resistance exercise with behaviour change strategies and symptom support)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study: 29590122

Group type: EXPERIMENTAL
Intervention: Six-minute walk distance >400 m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline six-minute walk distance Q4 (>430 m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Month 6 six-minute walk distance Q4 (>455 m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in six-minute walk distance at Month 6
Number of subjects: 0
Study: 27434081

Group type: EXPERIMENTAL
Intervention: 6-min stepper test (6MST)
Number of subjects: 31
Study: 25217875

Group type: EXPERIMENTAL
Intervention: EmbryoScope time‐lapse monitoring system (TMS)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Standard incubator (SI)
Number of subjects: 843
Study: 22875601

Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg single dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 20236598

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium + Neostigmine (0.04 mg/kg) and Atropine (0.02 mg/kg)
Number of subjects: 60
Study: 17563138

Group type: EXPERIMENTAL
Intervention: Posttreatment gambling behavior
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Alternative behavioral indicators
Number of subjects: 178
Study: 17707848

Group type: EXPERIMENTAL
Intervention: Depressed women with CHD (BDI score > or =19)
Number of subjects: 121
Study: 15065961

Group type: EXPERIMENTAL
Intervention: 16-week cognitive-behavioral treatment for primary anxiety disorders
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Positive responders to anxiety treatment
Number of subjects: 86
Study: 11876837

Group type: EXPERIMENTAL
Intervention: rhGH (0.1 mg . kg(‐1) subcutaneously at 10 pm every evening for 14 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9339609

Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bronchodilators only (Control)
Number of subjects: 0
Study: 1286545

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp (Hy)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Minimal model (MIN)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Shortened intravenous glucose tolerance test (IVGTT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous infusion of glucose with model assessment (C.I.G.M.A.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: All methodologies combined
Number of subjects: 17
Study: 3891346

Group type: EXPERIMENTAL
Intervention: Nifedipine treatment (10 mg orally at onset, after 30 min, then every 6 h)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nifedipine treatment
Number of subjects: 57
Study: 30705235

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including a 2-hour workshop on best-practice regarding BZD prescription, monthly feedback on prescribing practices, and access to a support web page
Number of subjects: 3

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3
Study: 29842796

Group type: EXPERIMENTAL
Intervention: 24-hour hospital stay (Group A)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Inpatient (Group B)
Number of subjects: 432
Study: 26864586

Group type: EXPERIMENTAL
Intervention: Mobilization exercises using the BALLance-Methode®
Number of subjects: 27

Group type: COMPARATOR
Intervention: Core stability exercises
Number of subjects: 27
Study: 24868146

Group type: COMPARATOR
Intervention: MMX mesalamine 4.8 g once daily
Number of subjects: 166
Study: 22915730

Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (case management providing crisis intervention and flexible problem solving, including motivational support and assistance with appointments)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (self-reported data)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard treatment (control group, self-reported data)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (imputed self-reported outcomes)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard treatment (control group, imputed self-reported outcomes)
Number of subjects: 243
Study: 20385632

Group type: EXPERIMENTAL
Intervention: HIE-erythropoietin group (2500 IU/kg, subcutaneously, daily for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HIE-control group (did not receive erythropoietin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal healthy group
Number of subjects: 30
Study: 17356051

Group type: COMPARATOR
Intervention: Basal plasma cortisol concentrations
Number of subjects: 177

Group type: COMPARATOR
Intervention: Cosyntropin-stimulated plasma cortisol concentrations
Number of subjects: 177
Study: 15241601

Group type: EXPERIMENTAL
Intervention: Gambling cues exposure in pathological gamblers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gambling cues exposure in healthy controls
Number of subjects: 0
Study: 11891019

Group type: EXPERIMENTAL
Intervention: 8 week circuit training (CT) program
Number of subjects: 16
Study: 10205211

Group type: EXPERIMENTAL
Intervention: Adrenaline injection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (gold probe)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined treatment (adrenaline injection and gold probe)
Number of subjects: 96
Study: 10155359

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 16

Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 16
Study: 2692728

Group type: EXPERIMENTAL
Intervention: Mitoxantrone at 14 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitoxantrone at 8 mg/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal bilirubin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study group with severe hepatic dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECOG level 0-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECOG level 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study: 270863

Group type: EXPERIMENTAL
Intervention: MTX + hydrocortisone IT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MTX + hydrocortisone IT + TCT
Number of subjects: 24

Group type: COMPARATOR
Intervention: No prophylactic treatment (previous series)
Number of subjects: 24
Study: 30874471

Group type: EXPERIMENTAL
Intervention: Bolus dose epinephrine (BDE)
Number of subjects: 4374

Group type: COMPARATOR
Intervention: Control (no BDE)
Number of subjects: 4374
Study: 30371381

Group type: EXPERIMENTAL
Intervention: Progressive thresholding neurofeedback protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current automatic reward thresholding algorithms
Number of subjects: 0
Study: 26855267

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (100mg caffeine)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo chewing gum (non-caffeinated)
Number of subjects: 23
Study: 25845088

Group type: EXPERIMENTAL
Intervention: Structured exercise training (3 times/week for the first 3 months, then once/week for the following 9 months)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (general lifestyle intervention suggestions)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Structured exercise training (adherence level stratification)
Number of subjects: 94
Study: 22404061

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (130/0.4)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 7000
Study: 20216298

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 500 mg/night titrated to 1500 mg/night for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no ERN)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 19
Study: 18065594

Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g levocarnitine once daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15855557

Group type: EXPERIMENTAL
Intervention: 4 mg repaglinide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg and 4 mg repaglinide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 mg and 1 mg repaglinide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12393571

Group type: EXPERIMENTAL
Intervention: Screened patients for drug-dependent antibodies (DDABs)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Nonscreened patients
Number of subjects: 1044
Study: 10861613

Group type: EXPERIMENTAL
Intervention: Subdermal injection of radiotracer on the tumor site plus a second injection of radiotracer (varied by group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Different route of injection (peritumoral or subdermal) on the tumor site
Number of subjects: 30
Study: 10999057

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, 6 hourly for 7 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard antibiotic therapy (Control)
Number of subjects: 75
Study: 1862191

Group type: EXPERIMENTAL
Intervention: Special video program based on perceptions of the effects of smoking during pregnancy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: American Lung Association's 'Freedom From Smoking For You and Your Baby' program
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual physician's advice
Number of subjects: 193
Study: 6314799

Group type: EXPERIMENTAL
Intervention: Neutron boost radiotherapy after 50 Gy photon, whole-brain irradiation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Photon boost radiotherapy after 50 Gy photon, whole-brain irradiation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Photon boost group
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Neutron boost group
Number of subjects: 158
Study: 31553234

Group type: EXPERIMENTAL
Intervention: Olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity, or another discontinuation criterion.
Number of subjects: 0
Study: 30249825

Group type: EXPERIMENTAL
Intervention: TPKE mode (n = 54)
Number of subjects: 108

Group type: COMPARATOR
Intervention: LPKE mode (n = 54)
Number of subjects: 108
Study: 26980371

Group type: EXPERIMENTAL
Intervention: LY2495655 105 mg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LY2495655 315 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LY2495655
Number of subjects: 400
Study: 24458011

Group type: EXPERIMENTAL
Intervention: Treprostinil (delivered via cutaneous iontophoresis)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12